Houben-Wilke, Sarah
Janssen, Daisy J. A.
Franssen, Frits M. E.
Vanfleteren, Lowie E. G. W.
Wouters, Emiel F. M.
Spruit, Martijn A.
Funding for this research was provided by:
Lung Foundation Netherlands (3.4.10.015)
GlaxoSmithKline (SCO115406)
Article History
Received: 29 May 2018
Accepted: 17 October 2018
First Online: 30 October 2018
Ethics approval and consent to participate
: The COPD, health status and co-morbidities (Chance) study was approved by the local ethics committee of Maastricht University Medical Centre+, The Netherlands (MEC11–3-070). All patients gave written informed consent.
: Not applicable.
: FMEF discloses consulting and speaker fees from Novartis, GlaxoSmithKline, AstraZeneca, Chiesi, Boehringer Ingelheim and Teva. LEGWV discloses speaker fees from Chiesi, Novartis, GlaxoSmithKline and AstraZeneca. EFMW discloses consulting and speaker fees from Nycomed, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Novartis and Chiesi. MAS discloses speaker fees from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca. SH-W and DJAJ have nothing to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.